Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a headband at home keep depression away?

NCT ID NCT07269964

Disease control Sponsor: Technical University of Munich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether a portable, at-home brain stimulation device (tDCS) can help people with depression maintain the improvements they achieved during hospital treatment with esketamine, rTMS, or ECT. Thirty adults will use the device for 30 minutes a day, five days a week, for four weeks. The main goal is to see if the home program is feasible and well tolerated, and whether depressive symptoms stay stable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS) device
What this could lead to
If it works, this could offer a convenient, home-based way to help people with depression keep their gains after intensive hospital treatment.
What could go wrong
This is a very small, early pilot study (30 people) with no placebo group. It only tests feasibility, not proven effectiveness. The device may cause mild tingling or skin redness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years). * Diagnosis according to ICD-10: recurrent depressive disorder, severe depressive disorder, schizoaffective disorder (depressive episode) or bipolar affective disorder (depressive episode). * Clear indication for maintenance therapy after successful acute treatment (esketamine, rTMS, or ECT) with remission/improvement of symptoms. * Capacity to provide informed consent, confirmed in a physician-led consent discussion. Exclusion Criteria: * Currently in the acute treatment phase of an affective disorder and non-response to previous treatments. * Currently clinically relevant Axis II disorders. * Suicidal risk, including suicidal ideation. * Contraindications for tDCS: e.g., skin disease at electrode sites, cochlear implants. * Neurological, somatic, or psychiatric comorbidities that could compromise validity or safety.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar affective disorder (depressive episode) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression endogenous depression major affective disorder 6 major depressive disorder schizoaffective disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive episode MDD Severe depression

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Psychiatry and Psychotherapy, Technical University of Munich, University Hospital

    RECRUITING

    München, 81675, Germany

  • Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Munich,

    ENROLLING_BY_INVITATION

    München, Bavaria, 81675, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.